Connect with us

Hi, what are you looking for?

Jewish Business News


Israel’s Algae-Based Medical Adhesives Developer Sealantis Sold for $25 Million

Sealantis uses an algae-based polymer that does not contain proteins, reducing risks of infection or allergic reaction

Sealantis, (L-R) Dr. Ohad Kimhi, R&D Director, Prof. Havazelet Bianco-Peled, Founder and Chief Scientific Adviser, and Tomer Fuchs, CEO

Israel-based medical adhesives Sealantis was acquired by Advanced Medical Solutions Group (AMS) from Winsford, U.K. for $25 million and royalties from future sales, the two companies announced Thursday.

Sealantis develops medical adhesives based on patented technology from the Technion Israel. The leading advantage of the technology is the fact that it uses an algae-based polymer with no proteins, and therefore the risk of infection or allergy is significantly lower than that of competing products produced from animals. The product does not require refrigerated transport and storage, it can be applied by spreading or spraying, and is also suitable for use in laparoscopic surgery.

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at
Thank you.

Surgical glue, often used in place of sutures or staples, but the company focuses on surgical seals designed to stop bleeding, prevent leakage of digestive tract contents into the abdominal cavity, prevent leakage of spinal fluid, and a variety of other applications. The company’s pipeline is focused on two segments: gastrointestinal, to prevent intestinal leaks following surgery, and vascular, for rapid control of bleeding.

AMS, the acquiring company, is a manufacturer of innovative and technologically advanced products for the global surgical, wound closure and advanced wound care markets. This is their first acquisition in Israel, and Sealantis will be an innovation center for the multinational group. AMS’s products are sold in more than 75 countries, and the group has more than 600 employees.

Founded in 2007 by Prof. Havazelet Bianco-Peled, Sealantis is London-listed which sells its products in over 75 countries. The company stated it intends to turn Sealantis into an innovation center and expand its operations in Israel.

Sealantis is developing a proprietary platform of alga-mimetic tissue adhesives, for a variety of applications and clinical needs in surgical leakage control, tissue adhesion and drug delivery. The Sealantis adhesives are protein-free, and have an extraordinary ability to adhere strongly to internal tissues even in wet environments.





You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


The Movie The Professional is what made Natalie Portman a Lolita.


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.